Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Growth in Short Interest
Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Growth in Short Interest
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 3,470,000 shares, an increase of 20.9% from the November 30th total of 2,870,000 shares. Based on an average daily volume of 587,600 shares, the short-interest ratio is currently 5.9 days. Currently, 4.1% of the shares of the stock are sold short.
Cytek Biosciences, Inc.(納斯達克股票代碼:CTKB — 獲取評級)在12月份空頭利率大幅增加。截至12月15日,空頭利息共計347萬股,較11月30日的287萬股增加了20.9%。根據587,600股的平均每日成交量,目前的空頭利率爲5.9天。目前,該股4.1%的股票被賣空。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Separately, Piper Sandler boosted their price target on shares of Cytek Biosciences from $16.00 to $18.00 in a research report on Monday, November 14th.
另外,派珀·桑德勒在11月14日星期一的一份研究報告中將其Cytek Biosciences股票的目標股價從16.00美元上調至18.00美元。
Insider Buying and Selling
內幕買入和賣出
In related news, CFO Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock in a transaction dated Tuesday, December 27th. The stock was sold at an average price of $9.77, for a total value of $34,195.00. Following the sale, the chief financial officer now directly owns 79,632 shares in the company, valued at approximately $778,004.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Jack Ball sold 16,000 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $14.69, for a total value of $235,040.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company's stock, valued at approximately $44,070. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of $9.77, for a total value of $34,195.00. Following the completion of the transaction, the chief financial officer now owns 79,632 shares in the company, valued at approximately $778,004.64. The disclosure for this sale can be found here. Insiders sold a total of 146,500 shares of company stock worth $1,989,745 in the last 90 days. Insiders own 15.90% of the company's stock.
在相關新聞方面,首席財務官帕特里克·讓莫諾德在12月27日星期二的交易中出售了3500股Cytek Biosciences的股票。該股以9.77美元的平均價格出售,總價值爲34,195.00美元。出售後,首席財務官現在直接擁有該公司79,632股股份,價值約778,004.64美元。該交易已在向美國證券交易委員會提交的法律文件中披露,該文件可在以下網址查閱 這個鏈接。在相關新聞方面,董事傑克·鮑爾在11月14日星期一的一筆交易中出售了16,000股股票。該股的平均價格爲14.69美元,總價值爲235,040.00美元。交易完成後,董事現在直接擁有該公司3,000股股票,價值約44,070美元。該交易已在向美國證券交易委員會提交的文件中披露,該文件可通過以下方式查閱 美國證券交易委員會網站。此外,首席財務官帕特里克·讓莫諾德在12月27日星期二的一筆交易中出售了該公司3500股股票。這些股票的平均價格爲9.77美元,總價值爲34,195.00美元。交易完成後,首席財務官現在擁有該公司79,632股股份,價值約778,004.64美元。此次出售的披露信息可以找到 這裏。在過去的90天裏,業內人士共出售了146,500股公司股票,價值1,989,745美元。業內人士擁有該公司15.90%的股份。
Hedge Funds Weigh In On Cytek Biosciences
對沖基金對 Cytek Biosciences 施加
Cytek Biosciences Price Performance
Cytek 生物科學的性價比
Cytek Biosciences stock traded down $0.09 during trading on Monday, reaching $10.21. 8,344 shares of the company were exchanged, compared to its average volume of 786,226. The stock's 50 day simple moving average is $12.89 and its two-hundred day simple moving average is $12.96. The company has a market capitalization of $1.38 billion, a P/E ratio of -1,021.00 and a beta of 0.06. Cytek Biosciences has a 52-week low of $7.38 and a 52-week high of $17.41.
Cytek Biosciences的股票在週一的交易中下跌了0.09美元,至10.21美元。該公司交換了8,344股股票,而平均成交量爲786,226股。該股的50天簡單移動平均線爲12.89美元,其兩百天簡單移動平均線爲12.96美元。該公司的市值爲13.8億美元,市盈率爲-1,021.00,beta爲0.06。Cytek Biosciences創下52周低點7.38美元,52周高點爲17.41美元。
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.01). The company had revenue of $40.48 million during the quarter, compared to analyst estimates of $43.36 million. Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. As a group, equities analysts forecast that Cytek Biosciences will post 0.01 earnings per share for the current year.
Cytek Biosciences(納斯達克股票代碼:CTKB — 獲取評級)最後一次發佈財報是在11月9日星期三。該公司公佈的本季度每股收益(EPS)爲0.01美元,低於分析師共識估計的0.02美元(0.01美元)。該公司本季度的收入爲4,048萬美元,而分析師的估計爲4,336萬美元。Cytek Biosciences的正股本回報率爲0.94%,負淨利潤率爲0.47%。作爲一個整體,股票分析師預測,Cytek Biosciences今年將公佈每股收益0.01美元。
About Cytek Biosciences
關於 Cytek 生物科學
(Get Rating)
(獲取評級)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
細胞分析解決方案公司Cytek Biosciences, Inc提供細胞分析工具,促進生物醫學研究和臨床應用的科學進步。它提供極光和北極光系統,即光譜流式細胞儀,通過利用來自多個激光器的熒光信號來區分單個細胞上的熒光標籤來進行細胞分析;以及極光細胞分選系統,該系統利用全光譜分析技術進一步擴大細胞分析的潛在應用。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 免費獲取 StockNews.com 關於 Cytek Biosciences (CTKB) 的研究報告
- MarketBeat:本週回顧 12 月 26 日 — 12 月 30 日
- 科技之狗:是時候咬一口這些股票了
- 此次收購會使微軟成爲熊市買入嗎?
- 金塔拉療法是隱藏的寶石嗎?
- 你應該爲冬天的 Generac Stock 做熱身嗎?
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Cytek 生物科學日報的新聞和評級 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Cytek Biosciences及相關公司的最新新聞和分析師評級的簡明每日摘要。